Moderna Inc said Thursday that it expects to have between 100 million and 125 million doses of its experimental COVID-19
vaccine available globally in the first quarter of 2021.
The company said 85 million to 100 million of those doses would be available in the United States, and 15 to 25 million outside the country.
The first-quarter doses are within the 500 million to 1 billion doses the company expects to manufacture globally in 2021, Moderna said.
Results from an early-stage trial showed that the vaccine, mRNA-1273, produced high levels of neutralizing and binding antibodies that decreased slightly over time, but remained elevated in all participants three months after the booster shot, he said. the company.
The drugmaker’s shares fell 2% to $ 154.4 after the bell.
Disclaimer: This post has been automatically published from an agency feed without any modifications to the text and has not been reviewed by an editor.
